Figure 1

A proposed model for how GPG-NH ₂ or its metabolites target gp160 for ERAD. Initially, gp160 is co-translationally translocated into the ER, where its growing peptide backbone becomes glycosylated and starts to fold. (1) In the presence of GPG-NH₂ or its metabolites gp160 folds incorrectly which targets it to ERAD. (2) Subsequently, gp160 is retro-translocated to the cytoplasm, (3) where it becomes deglycosylated by the cytosolic N-glycanase prior to (4) degradation of its peptide backbone by the proteasome.